{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:14:51Z","timestamp":1784837691951,"version":"3.55.0"},"reference-count":36,"publisher":"SAABRON PRESS","issue":"2-3","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Hematol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This round table discussion organized by the International Academy for Clinical Hematology (IACH) was dedicated to the 19th annual meeting of the International Myeloma Society (IMS), which was held in Los Angeles between the 25th and 27th August 2022. After some key meetings of the discipline of the field of clinical hematology, the IACH organizes regular round table discussion in order to summarize the flow of information and get the opinion of a panel of experts and the key take-home messages. As part of this discussion, the panellists debated 6 key topics: disease monitoring, management of high-risk multiple myeloma (MM), induction for newly-diagnosed MM, management of relapsed MM, immune reconstitution, and vaccination and cellular therapy in MM.\n<\/jats:p>","DOI":"10.1007\/s44228-023-00036-8","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T10:02:13Z","timestamp":1681552933000},"page":"112-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)"],"prefix":"10.46989","volume":"5","author":[{"given":"Nizar J.","family":"Bahlis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Harousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"issue":"suppl 1","key":"36_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood-2021-145494","volume":"138","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Chhabra S, Callander NS, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted consolidation and treatment cessation. Final primary end point analysis of the Master trial. Blood. 2021;138(suppl 1):481. https:\/\/doi.org\/10.1182\/blood-2021-145494.","journal-title":"Blood"},{"key":"36_CR2","unstructured":"MInimal Residual Disease Adapted Strategy (MIDAS) KRd-Isatuximab: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04934475"},{"issue":"4","key":"36_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139(4):492\u2013501. https:\/\/doi.org\/10.1182\/blood.2020010439.","journal-title":"Blood"},{"key":"36_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.V130.Suppl_1.435.435","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau H, Lauwers-Cances V, Corre J, Moreau P, Attal M, Munshi NC. Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial. Blood. 2017;130:435\u201345. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.435.435.","journal-title":"Blood"},{"issue":"15 suppl","key":"36_CR5","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2017.35.15_suppl.8011","volume":"35","author":"S Oliva","year":"2017","unstructured":"Oliva S, Hofste op Bruinink D, \u0158\u00cdhov\u00e1 L, Spada S, van der Holt B, Troia R, et al. Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02\/HO95 phase 3 trial. J Clin Oncol. 2017;35(15 suppl):8011.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"36_CR6","doi-asserted-by":"publisher","first-page":"TPS8056","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8056","volume":"37","author":"S Zweegman","year":"2019","unstructured":"Zweegman S, Usmani SZ, Chastain K, Carey J, Ren K, Smith E, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS). J Clin Oncol. 2019;37(15_suppl):TPS8056.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"36_CR7","doi-asserted-by":"publisher","first-page":"TPS8055","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8055","volume":"36","author":"RZ Orlowski","year":"2018","unstructured":"Orlowski RZ, Goldschmidt H, Cavo M, Martin TG, Paux G, Oprea C, Facon T. Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). J Clin Oncol. 2018;36(15_suppl):TPS8055. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.TPS8055.","journal-title":"J Clin Oncol"},{"issue":"18","key":"36_CR8","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133(18):1953\u201363. https:\/\/doi.org\/10.1182\/blood-2018-09-874396.","journal-title":"Blood"},{"issue":"10","key":"36_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/s1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317\u201330. https:\/\/doi.org\/10.1016\/s1470-2045(20)30452-6.","journal-title":"Lancet Oncol"},{"key":"36_CR10","unstructured":"A study of daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by ciltacabtagene autoleucel versus daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by autologous stem cell transplant (ASCT) in participants with newly diagnosed multiple myeloma (CARTITUDE-6)"},{"key":"36_CR11","unstructured":"ClinicalTrials.gov Identifier: NCT05317416. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05317416"},{"issue":"26","key":"36_CR12","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"issue":"19","key":"36_CR13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1200\/JCO.18.00776","volume":"37","author":"A Perrot","year":"2019","unstructured":"Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien M-L, Royer B, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37(19):1657\u201365. https:\/\/doi.org\/10.1200\/JCO.18.00776.","journal-title":"J Clin Oncol"},{"issue":"29","key":"36_CR14","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/jco.21.02614","volume":"40","author":"M D'Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta J, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40(29):3406\u201318. https:\/\/doi.org\/10.1200\/jco.21.02614.","journal-title":"J Clin Oncol"},{"issue":"1","key":"36_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-020-00948-5","volume":"13","author":"K Weisel","year":"2020","unstructured":"Weisel K, Spencer A, Lentzsch S, Avet-Loiseau H, Mark TM, Spick I, et al. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J Hematol Oncol. 2020;13(1):115.","journal-title":"J Hematol Oncol"},{"issue":"15_suppl","key":"36_CR16","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2021.39.15_suppl.8002","volume":"39","author":"F Gay","year":"2021","unstructured":"Gay F, Mina R, Rota-Scalabrini D, Galli M, Belotti A, Zamagni E, et al. Carfilzomib-based induction\/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. J Clin Oncol. 2021;39(15_suppl):8002\u20138002. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8002.","journal-title":"J Clin Oncol"},{"issue":"8","key":"36_CR17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345. https:\/\/doi.org\/10.1182\/blood.2020005288.","journal-title":"Blood"},{"issue":"10192","key":"36_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1.","journal-title":"Lancet"},{"issue":"15_suppl","key":"36_CR19","doi-asserted-by":"publisher","first-page":"TPS8055","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055","volume":"37","author":"P Sonneveld","year":"2019","unstructured":"Sonneveld P, Broijl A, Gay F, Boccadoro M, Einsele H, Blade J, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS. J Clin Oncol. 2019;37(15_suppl):TPS8055. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS8055.","journal-title":"J Clin Oncol"},{"key":"36_CR20","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","volume":"36","author":"LB Leypoldt","year":"2022","unstructured":"Leypoldt LB, Besemer B, Asemissen AM, H\u00e4nel M, Blau IW, G\u00f6rner M, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT. Leukemia. 2022;36:885\u20138. https:\/\/doi.org\/10.1038\/s41375-021-01431-x.","journal-title":"Leukemia"},{"key":"36_CR21","unstructured":"Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (IsKia) http:\/\/clinicaltrials.gov\/show\/NCT04483739"},{"issue":"10","key":"36_CR22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Orio A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(17)30578-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"36_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","volume":"23","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Quach H, Mateos M-V, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23(1):65\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(21)00579-9.","journal-title":"Lancet Oncol"},{"issue":"10292","key":"36_CR24","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/s0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos M-A, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(21)00592-4.","journal-title":"Lancet"},{"issue":"6","key":"36_CR25","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","volume":"35","author":"M Dimopoulos","year":"2021","unstructured":"Dimopoulos M, Weisel K, Moreau P, Anderson LD Jr, White D, San-Miguel J, et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia. 2021;35(6):1722\u201331. https:\/\/doi.org\/10.1038\/s41375-020-01021-3.","journal-title":"Leukemia"},{"issue":"15_suppl","key":"36_CR26","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1200\/JCO.2021.39.15_suppl.8017","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Perrot A, San-Miguel JF, Beksac M, Spicka I, Leleu X, et al. Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). J Clin Oncol. 2021;39(15_suppl):8017\u20138017. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8017.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"36_CR27","doi-asserted-by":"publisher","first-page":"8029","DOI":"10.1200\/JCO.2022.40.16_suppl.8029","volume":"40","author":"NWCJ van de Donk","year":"2022","unstructured":"van de Donk NWCJ, Agha ME, Cohen AD, Cohen YC, Anguille S, Kerre T, et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B. J Clin Oncol. 2022;40(16_suppl):8029\u20138029. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8029.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"36_CR28","doi-asserted-by":"publisher","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","volume":"38","author":"PG Richardson","year":"2020","unstructured":"Richardson PG, Vangsted AJ, Ramasamy K, Trudel S, Mart\u00ednez J, Mateos M-V, et al. First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2020;38(15_suppl):8500\u20138500. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8500.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"36_CR29","doi-asserted-by":"publisher","first-page":"TPS8072","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072","volume":"40","author":"M-V Mateos","year":"2022","unstructured":"Mateos M-V, Bahlis NJ, Costa LJ, Perrot A, Pei L, Rubin ML, et al. Randomized, phase 3 study of teclistamab plus daratumumab versus investigator\u2019s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed\/refractory multiple myeloma MajesTEC-3. J Clin Oncol. 2022;40(16_suppl):TPS8072. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS8072.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"36_CR30","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2021.39.15_suppl.8006","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Raje NS, Costello C, Dholaria BR, Solh MM, Levy MY, et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). J Clin Oncol. 2021;39(15_suppl):8006\u20138006. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8006.","journal-title":"J Clin Oncol"},{"issue":"10","key":"36_CR31","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140(10):1104\u201318. https:\/\/doi.org\/10.1182\/blood.2022015956.","journal-title":"Blood"},{"key":"36_CR32","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Richter J, Trudel S, Cohen AD, Spencer A, Forsberg PA et al. 1924 Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study. In: 64th ASH Annual Meeting and Exposition, Saturday, December 10, 2022","DOI":"10.1182\/blood-2022-157547"},{"key":"36_CR33","doi-asserted-by":"crossref","unstructured":"Delforge M, Baz RC, Cavo M, Callander NS, Ghobadi A, Rodriguez-Otero P et al. 2323 KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma. 64th ASH Annual Meeting and Exposition Sunday, December 6, 2020.","DOI":"10.1182\/blood-2020-137156"},{"key":"36_CR34","unstructured":"Janssen Research and Development, LLC. A study comparing JNJ-68284528, a car-t therapy directed against b-cell maturation antigen (BCMA), versus pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) in participants with relapsed and lenalidomide-refractory multiple myeloma (CARTITUDE-4). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2022 March 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04181827. NLM Identifier: NCT04181827."},{"issue":"1","key":"36_CR35","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1182\/blood-2021-147412","volume":"138","author":"NS Raje","year":"2021","unstructured":"Raje NS, Berdeja JG, Rodriguez-Otero P, Green DJ, Jagannath S, Lonial S, et al. KarMMa-7, a Phase 1\/2, dose-finding and dose-expansion study of combination therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy for relapsed\/refractory multiple myeloma (RRMM). Blood. 2021;138(1):4830. https:\/\/doi.org\/10.1182\/blood-2021-147412.","journal-title":"Blood"},{"issue":"16 suppl","key":"36_CR36","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.1200\/JCO.2022.40.16_suppl.8013","volume":"40","author":"C Touzeau","year":"2022","unstructured":"Touzeau C, Krishnan A, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Evaluating teclistamab in patients with relapsed\/refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents. J Clin Oncol. 2022;40(16 suppl):8013\u20138013. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8013.","journal-title":"J Clin Oncol"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44228-023-00036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44228-023-00036-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44228-023-00036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:21:49Z","timestamp":1694424109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44228-023-00036-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":36,"journal-issue":{"issue":"2-3","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1007\/s44228-023-00036-8","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"15 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following conflicts of interest: Nizar J. Bahlis: Honoraria: Celgene, Janssen, AbbVie, Amgen, Sanofi, Takeda, Karyopharm Therapeutics, GlaxoSmithKline, Genentech\/Roche; Consulting or Advisory Role: Janssen, Celgene, Amgen, Sanofi, Takeda, Pfizer, Karyopharm Therapeutics; Research Funding: Janssen (Inst), Celgene (Inst). Luciano J. Costa: Honoraria: Amgen, Celgene, Janssen, Karyopharm Therapeutics, Sanofi; Consulting or Advisory Role: AbbVie, Amgen, Celgene, Karyopharm Therapeutics; Speakers' Bureau: Amgen, Sanofi; Research Funding: Janssen, Amgen. Aurore Perrot: Honoraria: Amgen, Celgene, Janssen, Sanofi, Takeda, GlaxoSmithKline, AbbVie; Research Funding: Takeda (Inst); Travel, Accommodations, Expenses: Sanofi, Amgen, Janssen, Takeda, Celgene. Cyrille Touzeau: Honoraria: Abbvie, Celgene, Amgen, Takeda, Janssen, Sanofi, Novartis, GlaxoSmithKline; Consulting or Advisory Role: Novartis, Amgen, Celgene, Abbvie, Takeda, Janssen, GlaxoSmithKline; Research Funding: Abbvie. Mohamad Mohty: Honoraria: Celgene, Amgen, Bristol Myers Squibb, Janssen, Takeda, Pfizer, Astellas Pharma, Novartis, Jazz Pharmaceuticals; Consulting or Advisory Role: Jazz Pharmaceuticals, Sanofi, MaaT Pharma, Novartis, Xenikos, Adaptive Biotechnologies, GlaxoSmithKline; Speakers' Bureau: Janssen, Sanofi, Jazz Pharmaceuticals; Research Funding: Sanofi (Inst), Roche (Inst), Jazz Pharmaceuticals (Inst). Thierry Facon, Jean-Luc Harousseau, and Salomon Manier declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}